Positive and Negative Regulation of the Cardiovascular Transcription Factor KLF5 by p300 and the Oncogenic Regulator SET through Interaction and Acetylation on the DNA-Binding Domain
0303 health sciences
Binding Sites
DNA, Complementary
Chromosomal Proteins, Non-Histone
Kruppel-Like Transcription Factors
Down-Regulation
Nuclear Proteins
Proteins
Acetylation
In Vitro Techniques
Models, Biological
Cell Line
Protein Structure, Tertiary
DNA-Binding Proteins
Mice
03 medical and health sciences
Mutagenesis, Site-Directed
Animals
Humans
Histone Chaperones
E1A-Associated p300 Protein
HeLa Cells
DOI:
10.1128/mcb.23.23.8528-8541.2003
Publication Date:
2003-11-12T02:03:12Z
AUTHORS (11)
ABSTRACT
Here we show a novel pathway of transcriptional regulation of a DNA-binding transcription factor by coupled interaction and modification (e.g., acetylation) through the DNA-binding domain (DBD). The oncogenic regulator SET was isolated by affinity purification of factors interacting with the DBD of the cardiovascular transcription factor KLF5. SET negatively regulated KLF5 DNA binding, transactivation, and cell-proliferative activities. Down-regulation of the negative regulator SET was seen in response to KLF5-mediated gene activation. The coactivator/acetylase p300, on the other hand, interacted with and acetylated KLF5 DBD, and activated its transcription. Interestingly, SET inhibited KLF5 acetylation, and a nonacetylated mutant of KLF5 showed reduced transcriptional activation and cell growth complementary to the actions of SET. These findings suggest a new pathway for regulation of a DNA-binding transcription factor on the DBD through interaction and coupled acetylation by two opposing regulatory factors of a coactivator/acetylase and a negative cofactor harboring activity to inhibit acetylation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (100)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....